Abigail (Abby) Zalenski

Abigail (Abby) Zalenski

Abigail (Abby) Zalenski

Advisor: Monica Venere


(614) 366-4011

210 Tzagournis
420 W. 12th Avenue
Columbus, OH 43210

Google Map

Areas of Expertise

  • Neuro-Oncology


  • BS in Neuroscience (2017), The Ohio State University


My research focuses on the most lethal primary brain tumor, glioblastoma. When a patient is treated for glioblastoma, there is a small population of tumor cells that are resistant to therapy and hence remain to drive tumor recurrence. Additionally, these cells are very invasive and will leave the primary tumor site before surgical resection of the tumor. Due to their resistance to therapy, these cells that have moved away from the primary tumor are able to repopulate the brain with tumors after treatment. My research focuses on understanding the invasive and proliferative properties of this aggressive and therapy-resistant subset of tumor cells. One way we are working to understand invasion is to study the interactions between the tumor itself, and the surrounding neural tissue.


2020 - Third Place Poster in Biological Sciences, The Ohio State University Edward F. Hayes Graduate Research Forum

2020 - Pelotonia Graduate Research Fellowship

2020 - Radiation Oncology Outstanding Trainee Journal Club Presentation, The Ohio State University

2018 - Travel Award, American Brain Tumor Association 

2017 - Dean’s Distinguished University Fellowship, The Ohio State University Graduate School (3-year award)


Zalenski AA, Venere M. (2021) Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on "Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity" by Garbarino et al. Transl Oncol. 14(9):101173.

Tallman MM, Zalenski AA, Deighen AM, Schrock MS, Mortach S, Grubb TM, Kastury PS, Huntoon K, Summers MK, Venere M. (2021) The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma. Cancer Lett. 499:232-242.

Tallman MM, Zalenski AA, Venere M. (2021) Cancer Stem Cells in Pediatric Brain Tumors. In: Debinski W, editor. Gliomas [Internet]. Brisbane (AU): Exon Publications; Chapter 3. Review.

Zalenski AA, Majumder S, De K, Venere M. (2020) An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics. Sci Rep. 10(1):13946.

De K, Grubb TM, Zalenski AA, Pfaff KE, Pal D, Majumder S, Summers MK, Venere M. (2019) Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/CCDH1 Activity and Pharmacologic Inhibition of APC/CCDH1/CDC20 Compromises Viability. Mol Cancer Res. 17(7):1519-1530.

Zalenski A, De K., Venere M. (2017) Not just another biomarker: the role of integrin alpha 7 in glioblastoma. Stem Cell Investigation, 4(12), 99-99. 2017.

People Filters: